Glucocorticoid Receptor Density Correlates with Health Risk Factors and Insulin Resistance in Caucasian and African American Subjects

Abstract

Activation of the hypothalamic-pituitary-adrenal axis leads to secretion of cortisol, which binds to peripheral glucocorticoid receptor and mediates a complex series of metabolic and immune effects. Cortisol also binds to receptors in the hypothalamus and pituitary, and inhibits further secretion of adrenocorticotropic hormone thus preventing an excessive response. Excess glucocorticoid effect is seen in Cushings disease, adrenal adenomas/carcinomas and in glucocorticoid resistance. Within such pathology there are health consequences of excessive glucocorticoid action, including obesity, hypertension, and glucose intolerance or diabetes. We hypothesized that increased glucocorticoid receptor in peripheral tissue might mediate an excess glucocorticoid effect in the absence of increased cortisol secretion. The objective of the study was to investigate the relationship between glucocorticoid receptor density in leukocytes and health risk indices relevant to obesity and diabetes in a sample of Caucasian and African American subjects. Comparison of glucocorticoid receptor concentration with subject body mass index, percentage body fat, waist circumference, insulin resistance, plasma cortisol levels, gender, and lipid profiles were conducted. Increased glucocorticoid receptor density significantly correlated with body mass index, percentage body fat, waist circumference, and insulin resistance. No significant correlation was observed for glucocorticoid receptor density with lipid profiles. Furthermore, no significant differences were observed in glucocorticoid receptor density between Caucasian and African American subjects or male and female participants. Our results show that high risk health conditions, such as obesity and type-2 diabetes, may be associated with a form of hypothalamic-pituitary-adrenal axis dysfunction, characterized by localized leukocyte glucocorticoid receptor over-expression.

Key words

glucocorticoid receptor - insulin resistance - leukocyte

• References

• 1 Strain GW, Zumoff B, Kream J et al. Sex difference in the influence of obesity on the 24 h mean plasma concentration of cortisol. Metabolism 1982; 31: 209-212
• 2 Reul JMHM, de Kloet ER. Two receptor systems for corticosterone in rat brain: micro-distribution and differential occupation. Endocrinology 1985; 117: 2505-2511
• 3 Dallman MF, Akana SF, Cascio CS et al. Regulation of ACTH secretion: variations on a theme of B. Recent Prog Horm Res 1987; 43: 113
• 4 Meaney MJ, Dioro J, Francis D et al. Early environmental regulation of forebrain glucocorticoid receptor gene expression: implications for adrenocortical responses to stress. Dev Neurosci 1996; 18: 49-72
• 5 Garlow SJ, Ciaranello RD. Transcriptional control of the rat serotonin-2 receptor gene. Mol Brain Res 1995; 31: 201-209
• 6 Pelaia G, Vatrella A, Cuda G et al. Molecular mechanisms of corticosteroid actions in chronic inflammatory airway diseases. Life Sciences 2003; 72: 1549-1561
• 7 Labeur M, Holsboer F. Molecular mechanisms of glucocorticoid receptor signaling. Medicina 2010; 70: 457-462
• 8 Jessop DS, Dallman MF, Fleming D et al. Resistance to glucocorticoid feedback in obesity. J Clin Endocrinol Metab 2001; 86: 4109-4114
• 9 Ashwell JD, Lu FW, Vacchio MS. Glucocorticoids in T cell development and function. Annu Rev Immunol 2000; 18: 309-345
• 10 Cooper MS, Stewart PM. 11β-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation. J Clin Endocrinol Metab 2009; 94: 4645-4654
• 11 Siegel JM, Hyg MS, Yancey AK et al. Overweight and depressive symptoms among African-American women. Preventive medicine 2000; 31: 232-240
• 12 Frazier B, Hsiao CW, Deuster PA et al. African Americans and Caucasian Americans: differences in glucocorticoid-induced insulin resistance. Horm Metab Res 2010; 42: 887-891
• 13 Morgan SA, Sherlock M, Gathercole LL. 11β-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle. Diabetes 2009; 58: 2506-2515
• 14 Tahrani AA, Bailey CJ, Del Prato S et al. Management of type 2 diabetes: new and future developments in treatment. Lancet 2011; 378: 182-197
• 15 Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254
• 16 Dai CY, Huang JF, Hsieh MY. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol 2009; 50: 712-718
• 17 Kim-Dorner S-J, Deuster PA, Zeno SA et al. Should triglycerides and the triglycerides to high-density lipoprotein cholesterol ratio be used as surrogates for insulin resistance. Metab Clin Exp 2009; 59: 299-304
• 18 Zhu SK, Wang Z, Heshka S et al. Waist circumference and obesity-associated risk factors among whites in the third National Health and Nutrition Examination Survey: clinical action thresholds. Am J Clin Nutr 2002; 76: 743-749
• 19 Pi-Sunyer FX. Obesity: criteria and classification. Proc Nutr Soc 2000; 59: 505-509
• 20 Eriksson J, Franssila-Kallunki A, Ekstrand A. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 1989; 321: 337-343
• 21 Lillioja S, Mott DM, Spraul M. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Prima Indians. N Engl J Med 1993; 329: 1988-1992
• 22 Maffei M, Halaas J, Ravussin E. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-induced subjects. Nat Med 1995; 1: 1155-1161
• 23 Kopelman PG, Grossman A, Lavender P et al. The cortisol response to corticotrophin-releasing factor is blunted in obesity. Clin Endocrinol (Oxf) 1988; 28: 15-18
• 24 Stewart PM, Boulton A, Kumar S et al. Cortisol metabolism in human obesity: impaired cortisone-cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 1999; 84: 1022-1027
• 25 Rosmond R, Dallman MF, Bjorntorp P. Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. J Clin Endocrinol Metab 1998; 83: 1853-1859
• 26 von Geldern TW, Tu N, Kym PR et al. Liver-selective glucocorticoid antagonists: a novel treatment for type 2 diabetes. J Med Chem 2004; 47: 4213-4230
• 27 Rask E, Olsson T, Soderberg S. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 2001; 86: 1418-1421
• 28 Rosenstock J, Banarer S, Fonseca VA. The 11β-hydroxysteroid dehydrogenase type 1 inhibitor incb13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 2010; 33: 1516-1522
• 29 Whorwood CB, Donovan SJ, Flanagan D et al. Increased glucocorticoid receptor expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic syndrome. Diabetes 2002; 51: 1066-1075
• 30 Ishizaki H, Kariya Y. Effects of peripheral blood polymorphonuclear leukocyte function and blood components in Japanese black steers administered ACTH in a cold environment. J Vet Med Sci 1999; 61: 487-492
• 31 Bonifazi M, Mencarelli M, Fedele V et al. Glucocorticoid receptor mRNA expression in peripheral blood mononuclear cells in high trained compared to low trained and untrained subjects. J Endocrinol Invest 2009; 32: 816-820
• 32 Yehuda R, Lowy MT, Southwick SM et al. Lymphocyte glucocorticoid receptor number in post-traumatic stress disorder. Am J Psychiatry 1991; 148: 499-504